Skip to main content

Table 2 Ig20Gly infusion and dosing parameters

From: Transitioning subcutaneous immunoglobulin 20% therapies in patients with primary and secondary immunodeficiencies: Canadian real-world study

  Initiation
(n = 23)a
Post-initiation
3 months
(n = 17)a
6 months
(n = 93)b
12 months
(n = 107)
Infusion parameters
 Infusion volume/infusion, median (IQR), ml 30 (30–40) 33 (24–45) 40 (25–50) 40 (30–50)
 Infusion duration, median (IQR), minutes 35 (15–58) 33 (15–45) 45 (29–63) 60 (30–65)
 Number of infusion sites/infusion, median (IQR)
  1 site, n (%)
  2 sites, n (%)
  3 sites, n (%)
  > 3 sites, n (%)
2 (2–3)
2 (10.5)
11 (57.9)
2 (10.5)
4 (21.1)
2 (2–4)
1 (7.1)
9 (64.3)
0
4 (28.6)
2 (2–3)
10 (12.7)
42 (53.2)
15 (19.0)
12 (15.2)
2 (2–3)
10 (11.5)
49 (56.3)
16 (18.4)
12 (13.8)
 Number of infusions/month/patient, median (IQR) 4 (4–4) 4 (4–4) 4 (4–4) 4 (4–4)
 Maximal infusion rate/site, median (IQR), ml/h 40.0 (35.0–45.0) 50.9 (50.9–50.9) 43.3 (32.7–58.0) 40.0 (34.0–59.0)
 Infusions, n (%), that were:
  Interrupted
  Slowed
  Neither slowed nor interrupted
  Unknown
0
0
12 (52.2)
11 (47.8)
0
0
12 (70.6)
5 (29.4)
0
1 (1.1)
72 (77.4)
20 (21.5)
1 (0.9)
1 (0.9)
76 (71.0)
29 (27.1)
Dosing parameters
 Weekly dose, median (IQR), g 7.5 (6.0–8.0) 6.5 (5.6–8.0) 8.0 (6.0–10.0) 8.0 (6.0–10.0)
 Weekly dose per kg, median (IQR), g/kg 0.1 (0.1–0.1) 0.1 (0.1–0.1) 0.1 (0.1–0.1) 0.1 (0.1–0.1)
 Dosing interval, n (%)
  Daily
  2–6 times/week
  Once weekly
  Every 2 weeks
  Other
0
5 (21.7)
16 (69.6)
2 (8.7)
0
0
2 (11.8)
13 (76.5)
2 (11.8)
0
1 (1.1)
19 (20.4)
65 (69.9)
7 (7.5)
1 (1.1)
0
19 (17.9)
81 (76.4)
4 (3.8)
2 (1.9)
 IgG trough levels, g/lc
  Median (IQR)
  Range
7.8 (7.4–10.7)d
0.8–12.1
11.5 (4.7–11.6)
4.7–11.6
9.5 (7.9–10.7)
5.0–14.4
8.8 (8.0–10.9)
3.6–14.5
  1. n is number of patients. Total n for each time point is based on available data
  2. a Cohort 1 only
  3. b Cohorts 1 and 2 only
  4. c Available data: initiation, n = 9; 3 months, n = 3; 6 months, n = 46; 12 months, n = 59
  5. d All patients were SCIG-experienced at initiation; this value is the result of prior SCIG treatment during the transition to Ig20Gly